InvestSMART

Immutep Limited (ASX: IMM) - ETF Exposure

Current share price for IMM : $0.024 0.002 (7.69%)+

Immutep Ltd (IMM) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a Phase III, clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG 3) related immunotherapies for cancer and autoimmune disease.

IMM General Information +

ASX Code IMM
Website N/A
Industry/Sector Biotechnology
Market Cap ($M) 35
IMM Share Price $0.024
Day High $0.026
Day Low $0.024
Last Close $0.026
IMM Share Price Movement $0.00 ( 7.69% )
Prices as at 16:40, 20 Nov 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to IMM

Immutep Limited (IMM) is held across 8 ETFs spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when IMM moves, funds like IMPQ, ISO, SSO and VAS that hold it can move with it.

For more concentrated exposure, ETFs such as IMPQ (eInvest Better Future (Managed Fund)) allocate about 0.5% to IMM , while the average exposure across all 8 ETFs that hold it is around 0.1% .

Top ETF holdings

Last updated: ETF data and holdings as at 18 November 2026

Own IMM directly or through an ETF?

How does holding Immutep Limited (IMM) shares directly compare to ETFs that include it?

IMM Direct
IMPQ
ASX
ISO
ASX
SSO
ASX
VAS
ASX
Holdings 1 company 42 holdings 222 holdings 220 holdings 334 holdings
IMM Weight 100% 0.5% 0% 0% 0%
Diversification Single Stock Broad Broad Broad Broad
Annual Cost Brokerage only - 0.55% p.a. 0.5% p.a. 0.07% p.a.
Approx. Yield 0% - 4.92% 10.49% 3.24%
Star Ratings - Not Rated starstarstar starstar starstarstarstarstar

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not IMM's direct yield. Annual cost uses each ETF's MER.

IMM Exposure on $10,000 investment

How a $10,000 investment in Immutep Limited (IMM) one week ago compares with ETFs that hold it.

Security Investment type Current price 7-day price movement Dollar change Value today
Immutep Limited (IMM) Direct share $0.024 -4% -$400 $9,600
eInvest Better Future (Managed Fund) (IMPQ) - $3.980 0% $0 $10,000
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO) Equity - Australia Small/Mid Cap $4.440 -8.26% -$826 $9,174
State Street SPDR S&P/ASX Small Ordinaries ETF (SSO) Equity - Australia Small/Mid Cap $12.790 -8.32% -$832 $9,168
Vanguard Australian Shares Index ETF (VAS) Equity - Australia $106.530 -5.37% -$537 $9,463

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Immutep Limited (IMM) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Immutep Limited (IMM) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Immutep Limited (IMM) price-sensitive announcements

IMM - Encouraging Disease-Free Survival in Phase II Sarcoma Trial
Immutep Limited announced encouraging updated results from the investigator-initiated EFTI
Immutep Limited (IMM)
19 Nov 2026 | 8:16 AM
IMM - IMP761 Late-Breaking Abstract at ACR shows T-Cell Inhibition
Immutep Limited announced positive late-breaking Phase I data for IMP761, its first-in-cla
Immutep Limited (IMM)
9 Nov 2026 | 8:29 AM
IMM - Immutep Quarterly Activities Report and Appendix 4C
Immutep Limited’s Quarterly Activities Report and Appendix 4C for Q1 FY27, dated 29 Octobe
Immutep Limited (IMM)
29 Oct 2026 | 8:04 AM
IMM - Immutep Receives A$2.16 million French R&D Tax Incentive
Immutep Limited announced that it received €1.36 million, approximately A$2.16 million, fr
Immutep Limited (IMM)
28 Oct 2026 | 11:11 AM

Immutep Limited (IMM) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Immutep Limited (IMM)
ORDINARY FULLY PAID
Health Care $35 Encouraging Disease-Free Survival in Phase II Sarcoma Trial 19 Nov 2026 8:16AM $0.023 $0.024 risen by 4.35%
Immutep Limited (IMM)
ORDINARY FULLY PAID
Health Care $35 Immutep Investor Update 18 Nov 2026 9:25AM $0.024 $0.024 fallen by 0%
Immutep Limited (IMM)
ORDINARY FULLY PAID
Health Care $35 Immutep Expands US Patents for Efti Combination Therapies 11 Nov 2026 9:17AM $0.024 $0.024 fallen by 0%
Immutep Limited (IMM)
ORDINARY FULLY PAID
Health Care $35 EFTISARC-NEO Survival Data reported in CTOS 2026 Abstract 11 Nov 2026 9:06AM $0.024 $0.024 fallen by 0%
Immutep Limited (IMM)
ORDINARY FULLY PAID
Health Care $35 IMP761 Late-Breaking Abstract at ACR shows T-Cell Inhibition 9 Nov 2026 8:29AM $0.021 $0.024 risen by 14.29%
Immutep Limited (IMM)
ORDINARY FULLY PAID
Health Care $35 Upcoming Poster Presentations at CTOS and ESMO IO 2026 5 Nov 2026 8:24AM $0.021 $0.024 risen by 14.29%

IMM Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2028F C2 -$2.30 3.50% 0.00 0.00 0.00% 0.0%
2027F C2 -$2.30 -56.40% 0.00 0.00 0.00% 0.0%
2026A -$76.21 -$5.20 22.80% 0.00 0.00 0.00% 0.0%

IMM Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2026 A 2027 F 2028 F 2026 A 2027 F 2028 F 2026 A 2027 F 2028 F
CSL Limited (CSL) $95,905M 0.7309 -0.4349 0.0602 12.3811 21.9110 20.6672 2.13% 2.15% 2.22%
Immutep Limited (IMM) $38M 0.2275 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mesoblast Limited (MSB) $2,219M -0.4501 0.0000 0.0000 0.0000 0.0000 775.0000 0.00% 0.00% 0.00%
PYC Therapeutics Limited (PYC) $1,605M -0.3971 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $4,499M -1.3893 0.0000 -0.5234 0.0000 154.4393 324.0196 0.00% 0.00% 0.00%

IMM Directors

Name Position Start Date
Mr Marc Voigt Chief Financial Officer, Chief Executive Officer, Executive Director 9 Jul 2014
Professor Frederic Triebel Executive Director 13 Sep 2022
Dr Russell J Howard Non-Executive Chairman, Non-Executive Director 8 May 2013
Ms Lis (Elisabeth) Boyce Non-Executive Director 11 Apr 2023

Immutep Limited (IMM) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
18 Sep 2024 VOIGT, Marc Buy Indirect Shares 29,500 $0.340 $10,030.000
16 Mar 2020 CHAMBERLAIN, Grant Buy Indirect Shares 360,623 $0.277 $99,755.740
6 Aug 2019 CHAMBERLAIN, Grant Issued Indirect Shares 401,635 $0.021 $8,434.335

See all changes in directors' interest & trades for Immutep Limited (IMM) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

IMM Management

Name Position
Deanne Miller Chief Operating Officer,Company Secretary,General Counsel
Christian Mueller Other Corporate Officer
Stephan Winckels Other Corporate Officer

IMM Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Immutep Limited (IMM). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
326,740,329 (22.17%) The Bank of New York Mellon Corporation

IMM Calendar of Events

Date Event
26 October 2027 Report (Annual)
25 October 2027 Report (Annual)
30 August 2027 Report (Annual)
30 August 2027 Report (Prelim)
24 February 2027 Report (Interim)
27 November 2026 AGM

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.